20.23
-0.55 (-2.65%)
| Previous Close | 20.78 |
| Open | 20.98 |
| Volume | 1,231,332 |
| Avg. Volume (3M) | 1,556,715 |
| Market Cap | 1,347,463,680 |
| Price / Earnings (Forward) | 1.11 |
| Price / Sales | 1.38 |
| Price / Book | 8.85 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -18.71% |
| Operating Margin (TTM) | -14.71% |
| Diluted EPS (TTM) | -2.79 |
| Quarterly Revenue Growth (YOY) | 22.30% |
| Total Debt/Equity (MRQ) | 320.75% |
| Current Ratio (MRQ) | 2.30 |
| Operating Cash Flow (TTM) | 13.94 M |
| Levered Free Cash Flow (TTM) | 67.48 M |
| Return on Assets (TTM) | -6.17% |
| Return on Equity (TTM) | -92.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | Tandem Diabetes Care, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | 1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 0.94% |
| % Held by Institutions | 111.68% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Paradice Investment Management Llc | 31 Mar 2025 | 1,649,907 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 59.00 (Canaccord Genuity, 191.65%) | Buy |
| Median | 24.00 (18.64%) | |
| Low | 20.00 (Wells Fargo, -1.14%) | Hold |
| 20.00 (Mizuho, -1.14%) | Hold | |
| Average | 29.00 (43.35%) | |
| Total | 3 Buy, 5 Hold | |
| Avg. Price @ Call | 19.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 16 Jun 2025 | 24.00 (18.64%) | Hold | 20.23 |
| Citigroup | 22 May 2025 | 24.00 (18.64%) | Hold | 20.64 |
| Baird | 01 May 2025 | 24.00 (18.64%) | Hold | 19.98 |
| Canaccord Genuity | 01 May 2025 | 59.00 (191.65%) | Buy | 19.98 |
| Piper Sandler | 01 May 2025 | 30.00 (48.29%) | Buy | 19.98 |
| Stifel | 01 May 2025 | 31.00 (53.24%) | Buy | 19.98 |
| Wells Fargo | 01 May 2025 | 20.00 (-1.14%) | Hold | 19.98 |
| Mizuho | 10 Apr 2025 | 20.00 (-1.14%) | Hold | 17.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Jun 2025 | Announcement | Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor |
| 06 May 2025 | Announcement | Tandem Diabetes Care Announces Upcoming Conference Presentations |
| 30 Apr 2025 | Announcement | Tandem Diabetes Care Announces First Quarter 2025 Financial Results |
| 03 Apr 2025 | Announcement | Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025 |
| 19 Mar 2025 | Announcement | Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes |
| 18 Mar 2025 | Announcement | Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |